From the Division of Diagnostic Imaging, Department of Nuclear Medicine.
Department of Genitourinary Medical Oncology.
Clin Nucl Med. 2021 Feb 1;46(2):e114-e115. doi: 10.1097/RLU.0000000000003342.
18F-Fluciclovine PET/CT has become a common diagnostic imaging study used in the evaluation of biochemical recurrence in prostate cancer since its approval in 2016. We present a case report of an 82-year-old man with history of both prostate and bladder cancer who presented for a fluciclovine study due to rising PSA levels. There was incidental detection of focal penile activity, and a subsequent urethral biopsy performed showed urothelial carcinoma, which was also seen on a subsequent MRI study.
18F-Fluciclovine PET/CT 自 2016 年批准以来，已成为前列腺癌生化复发评估中常用的诊断性影像学研究。我们报告了一例 82 岁男性病例，该患者既有前列腺癌病史又有膀胱癌病史，因 PSA 水平升高而进行 fluciclovine 研究。偶然发现阴茎局灶性活性，随后进行的尿道活检显示尿路上皮癌，随后的 MRI 研究也显示了这一点。
